Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term administration & dosage. Found 208 abstracts

no pagination
Schilder RJ, Gallo JM, Millenson MM, Bookman MA, Weiner LM, Rogatko A, Rogers B, Padavic-Shallers K, Boente M, Rosenblum N, Adams AL, Ciccotto S, Ozols RF. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol. 2001 Feb 15;19(4):1183-94.
Selvakumaran M, Bao R, Crijns AP, Connolly DC, Weinstein JK, Hamilton TC. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res. 2001 Feb 15;61(4):1291-5.
Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001 Oct;7(10):3012-24.
Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer. 2001 Nov 15;92(10):2639-47.
Szarka CE, Yao KS, Pfeiffer GR, Balshem AM, Litwin S, Frucht H, Goosenberg EB, Engstrom PF, Clapper ML, O'Dwyer PJ. Chronic dosing of oltipraz in people at increased risk for colorectal cancer. Cancer Detect Prev. 2001 Jan;25(4):352-61.
Tapiero H, Tew KD, Gate L, Machover D. Prevention of pathologies associated with oxidative stress and dietary intake deficiencies: folate deficiency and requirements. Biomed Pharmacother. 2001 Sep;55(7):381-90.
Treat J, Damjanov N, Huang C, Zrada S, Rahman A. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Huntingt). 2001 May;15(5 Suppl 7):44-8.
Von Roenn JH, Cianfrocca M. Treatment of Kaposi's sarcoma. Cancer Treat Res. 2001 Jan;104:127-48.
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Trope C, Tuxen MK, Vergote I, Vermorken JB, Willemse PH. [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Gynecol Obstet Fertil. 2000 Jul;28(7-8):576-83.
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
Haas NB, Manola J, Hudes G, Citrin DL, Kies MS, Davis TE. Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer. Am J Clin Oncol. 2000 Dec;23(6):589-92.
Langer CJ, McAleer CA, Bonjo CA, Litwin S, Millenson M, Kosierowski R, Blankstein K, Alexander R, Ozols RF. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC). Eur J Cancer. 2000 Jan;36(2):183-93.
Lewis NL, Meropol NJ. Oral fluoropyrimidines in cancer treatment. Cancer Invest. 2000 Jan;18(8):747-60.
Movsas B. Innovative treatment strategies in locally advanced and/or unresectable non-small cell lung cancer. Cancer control : journal of the Moffitt Cancer Center. 2000 Jan;7(1):25-34.
Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol. 2000 Jun;27(3 Suppl 7):3-7.
Ozols RF. The role of gemcitabine in the treatment of ovarian cancer. Semin Oncol. 2000 Feb;27(1 Suppl 2):40-7.
Schilder RJ, Goldberg M, Millenson MM, Movsas B, Rogatko A, Rogers B, Langer CJ. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung. Lung Cancer. 2000 Jan;27(1):37-45.
Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer. Semin Oncol. 2000 Jun;27(3 Suppl 7):8-10.
Bonin SR, Pajak TF, Russell AH, Coia LR, Paris KJ, Flam MS, Sauter ER. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group. Cancer. 1999 Mar 15;85(6):1226-33.
Hudes GR, Lipsitz S, Grem J, Morrisey M, Weiner L, Kugler JW, Benson A. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292). Cancer. 1999 Jan 15;85(2):290-4.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term administration & dosage

Human administration & dosage Female therapeutic use drug therapy pathology Antineoplastic Combined Chemotherapy Protocols Non-US Gov't Support Male US Gov't Support-PHS Middle Age Paclitaxel Aged Treatment Outcome Ovarian Neoplasms adverse effects Adult Carboplatin Prognosis Lung Neoplasms Survival Analysis Non-Small-Cell Lung Carcinoma adverse metabolism effects drug effects Neoplasms methods Randomized Controlled Trials Animal Fluorouracil mortality radiotherapy analogs & derivatives Disease-Free Survival chemically induced Squamous Cell Carcinoma Combined Modality Therapy therapy genetics Deoxycytidine Antineoplastic Antimetabolites Stomatitis Hematopoietic Stem Cell Transplantation Breast Neoplasms Uracil Colorectal Neoplasms therapeutic complications Adenocarcinoma Neoplasm Staging Molecular Sequence Data Survival Rate Drug Dose-Response Relationship Cisplatin prevention & control Disease Progression Topotecan Severity of Illness Index use pharmacokinetics Stomach Neoplasms Drug Administration Schedule Antineoplastic Agents Clinical Trials 80 and over Aged Area Under Curve Leucovorin Enzyme Induction Biotransformation Peptide Fragments Retinoids secretion Local Neoplasm Recurrence Cell Line Glutathione Granulocyte Colony-Stimulating Factor Immunohistochemistry Tetrahydrofolate Dehydrogenase Oxidative Stress Agranulocytosis Trans-Activation (Genetics) Salvage Therapy Cryotherapy Hospitalization dosage Pain Diet Prostatic Neoplasms Folic Acid Deficiency Follow-Up Studies Palliative Care Viral Load Prospective Studies etiology biosynthesis cytology Th1 Cells Amino Acid Sequence physiopathology Neoplastic Gene Expression Regulation Oral Administration Cell Division Practice Guidelines Nutritional Status Combination Drug Therapy Highly Active Antiretroviral Therapy Lymph Nodes Retrospective Studies US Gov't Support-Non-PHS NAD(P)H Dehydrogenase (Quinone) Cultured Tumor Cells Anthracyclines Neutropenia Liposomes Homocysteine immunology Tegafur DNA Interferons Skin Diseases HLA-A2 Antigen diagnosis Immunologic Adjuvants Anticarcinogenic Agents Adjuvant Chemotherapy Cytokines Thoracotomy Physical Examination enzymology physiology Multiple Drug Resistance Philadelphia Cell Lineage Phase III Clinical Trials Hematopoietic Stem Cell Mobilization Neoplasm Proteins Interferon-alpha Respiratory Tract Neoplasms Risk Factors CD4 Lymphocyte Count Phase I Clinical Trials Patient Selection Epithelial Cells Conformal Radiotherapy Doxorubicin Biological Tumor Markers Tetanus Toxoid secondary Hormone-Dependent Neoplasms
Last updated on Saturday, August 15, 2020